FREDERICK, Md., Aug. 28 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that Astonix Life Science, has signed a sales and distribution agreement to provide ActiPatch Therapy to the healthcare market in Singapore. The initial order has been shipped and introduction of ActiPatch to the market has been warmly received.
The interest in the benefits of ActiPatch by the Healthcare providers in Singapore has been strong enough to allow Astonix Life Science to move forward in their plan to increase their distribution territory ahead of schedule. They have recently signed an additional agreement for the healthcare market in Malaysia.
"At Astonix Life Science, we are driven by innovations in life sciences. We are proud to be the distributor of ActiPatch. Being able to offer ActiPatch to these markets is an important healing benefit. We are extremely proud to be associated with BioElectronics and the people behind ActiPatch," said Amelia Chew, Director of Astonix Life Science.
"The enthusiasm shown by Astonix Life Science in introducing ActiPatch to the Singapore healthcare market has generated a reciprocal excitement at BioElectronics. We are looking forward to a strong joint commitment to provide the accelerated healing benefits of ActiPatch to the people of Singapore and Malaysia," said Andrew Whelan, President of BioElectronics Corporation.
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a few cents per hour. The unique ActiPatch delivery system, using patented technology, provides a cost- effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
|SOURCE BioElectronics Corporation|
Copyright©2007 PR Newswire.
All rights reserved